Dextera Biosciences

👥 13 employees💰 Last funded Aug 2023
Biotechnology Research🌐 dexterabio.com
Website LinkedIn
Dextera Biosciences is developing a new category of drugs, Synthetic D-Proteins, to overcome the limitations of current drug modalities. Synthetic D-Proteins exhibit antibody-like specificity to a single therapeutic target but with the broad distribution of small molecules, all while being otherwise “invisible” to the rest of the body. The consequences are that we can deliver sustained antibody-like activity specifically to interstitial targets, enable oral delivery with complete metabolic stability, and extend therapeutic durability with no immunogenicity. We are focusing on debilitating diseases where significant unmet need remains due to the limitations of current drugs.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Dextera Biosciences?
Dextera Biosciences has 1 investors on record on gritt.io.
When did Dextera Biosciences last raise funding?
The most recent investment in Dextera Biosciences recorded on gritt.io was in August 2023.
What industry is Dextera Biosciences in?
Dextera Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.